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The sentinel lymph node biopsy has become the standard procedure in the staging and management of
axillary lymph nodes in early breast cancer. This procedure has been validated by several studies with an
accuracy of 95% and a false-negative rate ranging from 5 to 15%.
Aim of this study is to analyze the most updated results and open problems reported in literature in the
use of sentinel node biopsy in breast surgery.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Signiﬁcant innovations in breast tumor surgery have involved
the dissection of the axillary lymph nodes in the last few years.
After results of validation studies, the sentinel lymph node biopsy
(SLNB) instead of routine axillary dissection has quickly become the
new standard of care in early breast cancer. The concept of
conservation, which has been applied to the breast with the
successful development of quadrantectomy, now also involves the
axillary lymph nodes.
The histological status of the axillary lymph nodes is the
most important prognostic factor in patients with breast cancer
and it remains the most powerful predictor of recurrence and
survival.
Early diagnosis of breast cancer has led to an increased number
of dissections in which axillary nodes are free of disease. In this
situation, a surgical technique that reduces the extent of the
removed axillary tissue without losing prognostic information may
have a very good impact on the quality of life.
The sentinel lymph node biopsy has proved to be a reliable
alternative to the traditional axillary lymph node dissection with
regard to predicting the histological status of the remaining lymph
nodes in clinical T1/2 N0 breast cancers. The SLNB has theRovera).
ciates Ltd. Published by Elsevier Ltadvantage of reduced postoperative morbidity compared to the
traditional axillary lymph node dissection.2. Deﬁnition
The sentinel lymph node is the ﬁrst regional step of lymphatic
drainage and metastasis of a primary breast tumor. Although
usually an axillary lymph node and most commonly in the central
group of level I, the sentinel node may be of level II (behind the
pectoralis minor muscle), level III (infraclavicular), an intra-
mammary node, an intrapectoral (Rotter’s) node or an internal
mammary lymph node.
The rationale for the adoption of a sentinel node biopsy is that,
due to the progressive involvement of axillary nodes by the tumor
cells, the histology of the ﬁrst lymph node would be representative
of all the other axillary nodes.3. Indications
The sentinel lymph node biopsy is indicated in patients with
accreted diagnosis of ductal carcinoma and in patients with highly
suspicious diagnosis of carcinoma when the clinical and imaging
ﬁndings suggest that the lesion may be invasive. Patients who are
undergoing a mastectomy for extensive or high-grade ductal
carcinoma in situ or who have high probability of invasive carci-
noma might also be considered for SLNB. More importantly, the
patient should have a clinically negative axilla by palpation. Thed. All rights reserved.
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a tumor measuring less than 3 cm of diameter.1
4. Contraindications
4.1. Tumor size
Most early studies limited the use of SLNB to T1 or T2 tumors.2
Although the incidence of lymph node metastasis increases with
tumor size, the use of SLNB may be accurate in T2 and T3 tumors as
well.3 Two studies indicate that there is no signiﬁcant difference in
the identiﬁcation rate and false-negative rate in T3 tumors versus
T1 tumors.4
4.2. Inﬂammatory breast cancer
There are insufﬁcient data on women with inﬂammatory breast
cancer to recommend the use of SLNB in this situation. The false-
negative rate for patients with inﬂammatory breast cancer is
unacceptably high so the SLNB is not recommended in this situa-
tion until more data are available.
4.3. Clinically positive axilla
Suspicious palpable adenopathy is a contraindication to SLNB.
The lymphatics leading to these clinically positive lymph nodes
may be blocked and prohibit accurate mapping leading to a false-
negative result. When there are equivocal ﬁndings in the axilla, an
ultrasound and ﬁne needle aspiration may aid in the clinical deci-
sion-making obviating the need for SLNB when the lymph node is
malignant.2
4.4. Neoadjuvant chemotherapy
Recently there have beenmany reports focusing on the accuracy
of SLNB after neoadjuvant chemotherapy for advanced breast
cancers. In a small institutional case series, the rate of SLNB iden-
tiﬁcation after neoadjuvant chemotherapy has ranged from 85 to
96% and the false-negative rate has ranged from 0 to 33%.5,6 The
largest study is a retrospective chart review of 2411 patients with
operable breast cancers enrolled in the NSABP B-27 trial of
preoperative chemotherapy. In this study, 420 patients underwent
SLNB and of these, 340 patients had a complete axillary dissection.
The sentinel lymph node was identiﬁed in 85% of 340 patients with
a false-negative rate of 12%.7 Therefore SLNB can be proposed after
neoadjuvant treatment in patients with T2/3 breast cancers
without clinical or imaging evidence of nodal axillary involvement
before chemotherapy.
4.5. Multicentric disease
More recently, several suggested techniques have been
proposed to perform SLNB in this setting of patients. Subdermal,
intradermal and subareolar routes of tracer injection are associated
with greater success with a comparable false-negative rate. Several
small nonrandomized series in which such an approach was eval-
uated have demonstrated that the performance of SLNB is similar to
that for women with focal disease. Studies with larger patient
populations are indeed necessary.8,9
4.6. Ductal carcinoma in situ
The use of SLNB in ductal carcinoma in situ (DCIS) is still
controversial. DCIS by deﬁnition has little or no metastatic
potential and recurrence is quite low after adequate conservativesurgery. The SLNB may be appropriate in DCIS with foci of
microinvasion, deﬁned as those with a palpable mass, mammo-
graphic mass, histology suspicious but not diagnostic, multicentric
disease that required a mastectomy, or histology with high
nuclear grade.10
4.7. Prior breast or axillary surgery
The impact of prior breast or axillary surgery has not been well
characterized. Limited data suggest that a previous excisional
biopsy does not affect the success of SLNB.11 It is likely that more
extensive breast surgery such as mammoplasty would be associ-
ated with a higher false-negative rate. Although data suggest that
SLNB may be proposed in women who have had axillary surgery,
the success rate is likely to be lower.12 Therefore SLNB is not rec-
ommended in the setting of prior axillary surgery.
4.8. Pregnancy
Vital dyes should not be administered to pregnant women,
however radiolabeled colloid is proven to be safe because the dose
of radiation to the fetus is minimal.
5. The sentinel lymph node biopsy technique
The techniques to identify the sentinel axillary node in breast
cancer involve the use of technetium sulfur colloid and isosulfan
blue dye in the USA, and technetium-labeled albumin and patent
blue dye in Europe. The utilization of both radiocolloid and blue dye
increases recognition of the sentinel lymph nodes. Individual
surgeons and institutionsmay utilize either radiocolloid or blue dye
alone with equal success after appropriate training and experience.
Several different sites of injection of radiocolloid and/or blue are
currently in use: peritumoral, intratumoral, subcutaneous, intra-
dermal, and subareolar. The best success consists of injecting the
radiocolloid/blue dye in the subdermis above the tumor or in the
tissue immediately surrounding it. In cases where a previous biopsy
was performed, the radiotracer is injected in the original area. The
procedure consists of using varying doses of the radiolabeled
colloid, from 0.1 (3.7 MBq) to 3 milliCurie (mCi) (111 MBq), in
varying volumes of saline, from 0.1 to 5 ml. Close cooperation
between the nuclear medicine department and the surgeon is
necessary and recommended. Mammary and axillary lympho-
scintigraphy are taken after 30 min up to 2–4 h after injection. The
interval between injection of radiocolloid and the operation also
varies, from 2 h to a full 24 h day before surgery is undertaken.
When blue dye is used, the mean volume is 3–4 ml. The time
between the injection and the axillary incision also varies,
depending upon patient size and the location of the tumor in the
breast.
A small incision of 1.5–2 cm is sufﬁcient to explore the axilla
with the probe which is in the proximity of the sentinel node that
gives out a recognizable acoustic signal. Removal of the sentinel
lymph nodemay be often obtained through the same incisionmade
for the removal of the primary breast carcinoma, especially if it lies
in the upper outer quadrants.
It is important to differentiate ‘failed’ and ‘false-negative’
terminology with regard to SLNB. The latter term deﬁnes the
identiﬁcation of sentinel nodes that are intraoperatively negative
but, upon further ﬁnal pathology exam of the processed lymphoid
material, they contain metastatic disease. ‘Failed’ SLNB implies the
inability to identify the sentinel lymph nodes. The ‘failed’ SLNB
usually leads to an immediate traditional axillary node dissection.
The radiation exposure to patients, surgeons, operating room
personnel and the staff of the pathology and nuclear medicine
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extremely low.
6. Pathology
In response to SLNB, new surgical pathology protocols have
emerged to censure that the intraoperative examination of the
sentinel lymph node is as accurate as possible. Recently, added to
the routine hematoxylin and eosin staining of lymph nodes has
been the additional examination of the lymph nodes by cytokeratin
immunohistochemistry (IHC) staining or polymerase chain reac-
tions. These techniques may assist in detecting single malignant
cells or few foci of tumor clusters. Each sentinel node is measured
and cut along its longitudinal axis into sections of 1.5–2 mm of
thickness. The lymph node sections are then entirely submitted in
formalin for parafﬁn section histology. The immunohistochemical
technique should not be considered standard practice (even if few
USA pathology departments do it routinely), but may be performed
when the hematoxylin and eosin stained slides have suspicious
cells that are equivocal.
7. Review of relevant literature
Initial results on SLNB in breast carcinoma and many later
studies indicated that this is a reliable axillary staging technique.
The reported accuracy ranges from 90 to 95% and false-negative
rates range from 5 to 15% even if the goal for false-negative should
be <5%. To date, only one prospective randomized clinical trial has
been published.13 Veronesi et al. randomly assigned 516 patients
with tumors of 2 cm or less to either SLNB and axillary dissection or
SLNB followed by axillary dissection, only if the SLN contained
metastases. For the patients who had SLNB and axillary dissection,
the false-negative rate was 8.8%. There were fewer axillary
complications and less morbidity in the group that had axillary
dissection only if SLN was positive for disease. For patients who did
not have axillary dissection, there were no axillary recurrences and
the short-term survival was the same as for the patients with
tumor-free lymph nodes who had axillary dissection. Three large
randomized trials on SLNB are currently ongoing.
The ALMANAC trial, begun in November 1999, is a randomized
multicenter trial in the UK comparing SLNB with conventional
axillary dissection in clinically node-negative patients. In total,1031
patients have been randomized. The authors concluded that SLNB
is associated with less armmorbidity and a better quality of life and
is cost-effective compared with standard axillary treatment.
The second trial is named NSABP-32 and is a phase III,
randomized trial which compares axillary resection with SLNB,
involving more than 5000 patients in North America. It began in
1999 and no preliminary results have been published as of yet.
The third trial, RACS SNAC, is a multicenter randomized trial of
the Royal Australian College of Surgeons, which recruited 789
women.
The recently reported meta-analysis demonstrates that, among
patients with positive SLN, 48.3% were found to have additional
node disease in axillar nodal dissection.12–14 Thus, routine axillary
dissection is recommended for patients with a positive SLN. More
problematic is the management of patients for whom the SLN is
positive only with the use of special studies, such as the immu-
nohistochemical (IHC) staining with antibodies to cytokeratins. IHC
analysis can upstage disease for approximately 10% of patients who
have a negative SLN. In the new American Joint Cancer Commission
(AJCC) staging system, the node classiﬁcation is not clinically
altered by clusters of isolated tumor cells of 0.2 mm or less. It
remains unclear if isolated tumor cells or micrometastases (lymph
node metastases of more than 0.2 mm but not larger than 2 mm)detected with hematoxylin and eosin staining or immunostains,
represent an adverse prognostic factor and whether axillary
dissection should be performed in all such cases. However,
metastasis is found in nonsentinel lymph nodes in approximately
10% of patients with isolated tumor cells in the SLN and in 20–35%
of patients with micrometastases in the SLN. Until further studies
addressing the clinical relevance of isolated tumor cells or micro-
metastases are complete, it is recommended that routine axillary
dissection for patients with micrometastases (>0.2 mm and
<2 mm) found on SLNB is completed.
To solve the problem of false-negative SLN on the ordinary
frozen section procedure, Veronesi et al. have proposed two solu-
tions.13 The ﬁrst is to have a complete examination of the sentinel
lymph node intraoperatively with a technique extensively in use at
the European Institute of Oncology. This technique consists of
a large series of sections at 50 mm intervals, so that all the node is
exhaustedly examined without the risk of micrometastases
escaping the histologic examination. This method is time-
consuming and expensive, but the avoidance of a second operation
in 20% of the cases largely compensates for extra costs. The second
solution proposed by Veronesi et al. is to perform the sentinel node
biopsy under local anaesthesia on an outpatient basis a few days
before the ﬁnal surgery.15 If the sentinel node is negative, surgery
will be limited to breast lumpectomy/quadrantectomy, again on an
outpatient basis, or to amastectomy; if the sentinel node is positive,
the ﬁnal surgery will include total axillary node dissection.8. Conclusion
Sentinel lymph node biopsy has been widely accepted as
a standard procedure for the staging and management of early
breast cancer.15–22 A routine sentinel lymph node process needs
a high level of competence and a sufﬁcient training program among
members of the surgery department, nuclear medicine and
pathology department. Many practical problems remain and details
of the technique are not yet standardized. Ongoing large clinical
trials will hopefully provide answers regarding numerous problems
in the near future.Conﬂict of interest
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